Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respirator ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...

ABC delivered the most reach for pharma, thanks to its coverage of the NBA playoffs and world news broadcasts.

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

His diet used to come in a juice box. Now, at 24, he’s learning how to eat, taste, and enjoy food for the first time — on ...

Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called ...

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.